8-K current report · filed Oct 22, 2026

Korro Bio, Inc. (KRRO) 8-K Current Report: October 22, 2026

Item 8.01Item EX-99.1KRRO overview

Short answer

Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). KRRO announced preclinical results for KRRO-111, its candidate for Alpha-1 Antitrypsin Deficiency.

Korro Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • KRRO announced preclinical results for KRRO-111, its candidate for Alpha-1 Antitrypsin Deficiency
  • Results represent an early development milestone, with clinical efficacy and safety still unestablished
  • Full data and investor-relevant findings are in Exhibit 99.1 accompanying the 8-K

Item EX-99.1 · Exhibit EX-99.1

  • KRRO-111 achieved 96% SERPINA1 mRNA editing in repeat-dose mice, with M-AAT comprising 93% of circulating AAT
  • Total AAT reached 172 μM, approximately 6-fold versus vehicle, at Day 57
  • Liver Z-AAT fell 95% versus vehicle, supporting potential to address both AATD lung and liver disease
  • Regulatory submission targeted for the first half of 2027, creating a key development catalyst
  • Human translation remains unproven, with results limited to preclinical mouse models and no head-to-head evidence for “best-in-class” claims

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Korro Bio, Inc. 8-K filings

Get the next KRRO 8-K as it lands

Follow KRRO for push alerts, or ask the research agent what this filing means.